company background image
DVAX logo

Dynavax Technologies NasdaqGS:DVAX Stock Report

Last Price

US$10.87

Market Cap

US$1.4b

7D

2.5%

1Y

-24.7%

Updated

17 Jul, 2024

Data

Company Financials +

Dynavax Technologies Corporation

NasdaqGS:DVAX Stock Report

Market Cap: US$1.4b

DVAX Stock Overview

A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.

DVAX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Dynavax Technologies Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dynavax Technologies
Historical stock prices
Current Share PriceUS$10.87
52 Week HighUS$15.15
52 Week LowUS$10.41
Beta1.28
11 Month Change-4.14%
3 Month Change-4.14%
1 Year Change-24.72%
33 Year Change12.18%
5 Year Change250.65%
Change since IPO-88.44%

Recent News & Updates

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Recent updates

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

Oct 16

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Oct 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Aug 10
Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Shareholder Returns

DVAXUS BiotechsUS Market
7D2.5%5.0%2.2%
1Y-24.7%15.2%22.6%

Return vs Industry: DVAX underperformed the US Biotechs industry which returned 13.6% over the past year.

Return vs Market: DVAX underperformed the US Market which returned 22% over the past year.

Price Volatility

Is DVAX's price volatile compared to industry and market?
DVAX volatility
DVAX Average Weekly Movement4.4%
Biotechs Industry Average Movement10.6%
Market Average Movement5.9%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: DVAX has not had significant price volatility in the past 3 months.

Volatility Over Time: DVAX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996408Ryan Spencerwww.dynavax.com

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.

Dynavax Technologies Corporation Fundamentals Summary

How do Dynavax Technologies's earnings and revenue compare to its market cap?
DVAX fundamental statistics
Market capUS$1.42b
Earnings (TTM)US$9.22m
Revenue (TTM)US$236.15m

154.3x

P/E Ratio

6.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DVAX income statement (TTM)
RevenueUS$236.15m
Cost of RevenueUS$98.47m
Gross ProfitUS$137.68m
Other ExpensesUS$128.46m
EarningsUS$9.22m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.07
Gross Margin58.30%
Net Profit Margin3.91%
Debt/Equity Ratio36.1%

How did DVAX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.